Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04691323 · ClinicalTrials.gov registry record · NA

The Longitudinal Relationship of HU Adherence to HRQOL, Barriers to Adherence and Habit in SCD.

A NA study of Sickle Cell Disease and Sickle Beta Zero Thalassemia, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.

Active
Registry status
NA
Development phase
68
Enrollment target
1
Study location

NCT04691323: Active NA study of Sickle Cell Disease and Sickle Beta Zero Thalassemia, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.

NCT04691323 is a NA study of Sickle Cell Disease and Sickle Beta Zero Thalassemia that is active but no longer recruiting, run by Ann & Robert H Lurie Children's Hospital of Chicago. The registered enrollment target is 68 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04691323, a NA study of Sickle Cell Disease and Sickle Beta Zero Thalassemia, is active but no longer recruiting, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
68 participants
Enrollment target
1
Study location

Study Summary

The primary objective of this study is to better understand factors contributing to variations in hydroxyurea (HU) adherence behavior in adolescents and young adults (AYA) with sickle cell disease (SCD). To meet this objective, the researchers will conduct a prospective cohort study to determine the longitudinal relationship between HU adherence and health-related quality of life (HRQOL) overtime among AYA with SCD. The long-term goal of this research is to promote medication adherence behavior and improve health outcomes in AYA with SCD.

Primary Outcome

Adherence rate is defined as number of given HU doses given, as captured by HU-Go app, divided by total number of doses expected during study period.

Conditions Studied

Sickle Cell Disease Sickle Beta Zero Thalassemia Sickle B+ Thalassemia Sickle Cell Hemoglobin C

Interventions

  • OTHER HU-Go app

Study Locations (1)

Illinois

  • Ann & Robert H Lurie Children's Hospital of Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 68 participants
Start Date 2021-03-02
Est. Completion 2025-12-01
Phase NA
Ann & Robert H Lurie Children's Hospital of Chicago

159 total trials

What the registry record for NCT04691323 still lists

NCT04691323 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (77% lower).

The record links to 4 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which HU-Go app is the first listed.

NCT04691323 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT04691323 about?

NCT04691323 is a clinical study titled "The Longitudinal Relationship of HU Adherence to HRQOL, Barriers to Adherence and Habit in SCD.". The primary objective of this study is to better understand factors contributing to variations in hydroxyurea (HU) adherence behavior in adolescents and young adults (AYA) with sickle cell disease (SCD). To meet this objective, the researchers will conduct a prospective cohort study to determine the...

What is the current status of trial NCT04691323?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 68 participants. The study started on 2021-03-02. Estimated completion is 2025-12-01.

What conditions does trial NCT04691323 study?

This clinical trial studies the following conditions: Sickle Cell Disease, Sickle Beta Zero Thalassemia, Sickle B+ Thalassemia, Sickle Cell Hemoglobin C.

What interventions are being tested in trial NCT04691323?

The interventions under investigation include: HU-Go app (OTHER).

Who is sponsoring clinical trial NCT04691323?

This trial is sponsored by Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04691323 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04691323's enrollment target sits among peer trials

68 88th of 213 higher than 125 of 213 other Sickle Cell Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02044497 · 68 participants · Phase 4

    Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients

  • NCT03779854 · 68 participants · Phase 2

    Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

  • NCT03821246 · 68 participants · Phase 2

    Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

  • NCT04115514 · 68 participants · Phase 2

    Treatment of ARDS With Instilled T3

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04691323, the US trial registry maintained by the National Library of Medicine. NCT04691323 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.